1. Alvarnes JC. Healthcare perspective. In: Salgia R, editor. Oncology in the precision medicine era value-based medicine. Switzerland: Springer Nature; 2020. p. 1–12.
2. PriceWaterhouse Coopers. The new science of personalized medicine. New York: PriceWaterhouse Coopers; 2008. Available from http://www.pwc.com/us/en/healthcare/publications/personalized-medicine.html.
3. Trusheim MR, Berndt ER, Douglas FL. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat Rev Drug Discov. 2007;6:287–93.
4. McKinsey & Company. Personalized medicine: the path forward. Washington, DC: McKinsey & Company; 2013. Available from http://www.mckinsey.com/~/media/McKinsey/dotcom/client_service/Pharma%20and%20Medical%20Products/PMP%20NEW/PDFs/McKinsey%20on%20Personalized%20Medicine%20March%202013.ashx.
5. Gorry P, Useche D. Orphan drug designation as valuable intangible assets for IPO investors in Pharma-Biotech companies. In: Berndt ER, Goldman DP, Rowe JW, editors. Economic dimensions of personalized and precision medicine. Chicago: University of Chicago Press; 2019. p. 305–34.